^
    Back
    Association details:
    Biomarker:HR positive
    Cancer:HER2 Negative Breast Cancer
    Drug Class:PI3K inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ESMO-BC-I 2020
    Title:

    162P - Overcoming resistance to endocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: A meta-analysis of randomized clinical trials

    Published date:
    05/24/2020
    Excerpt:
    ...a meta-analysis and systemic review on randomized controlled trials (RCT) evaluating various targeted therapies in combination with ET in HR+/HER2- ABC. Moderate improvement in PFS (pooled HR 0.744, p=0.000, I2=0.0%) yet pronounced toxicities (pooled OR 2.154, p=0.000, I2=37.1%) were noted in the combination of phosphatidylinositol-4,5-bisphosphate 3-kinase inhibitors with fulvestrant.
    Secondary therapy:
    fulvestrant